- Home
- CNTA
as of 01-07-2026 3:57pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 3.7B | IPO Year: | 2021 |
| Target Price: | $37.70 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.60 - $30.58 | Next Earning Date: | 11-05-2025 |
| Revenue: | $15,000,000 | Revenue Growth: | 118.88% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered CNTA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
President, Orexin Program
Avg Cost/Share
$28.95
Shares
10,000
Total Value
$288,288.91
Owned After
181,369
General Counsel
Avg Cost/Share
$27.64
Shares
6,000
Total Value
$165,835.20
Owned After
105,386
SEC Form 4
Chief Technology & Quality Ofc
Avg Cost/Share
$28.00
Shares
40,000
Total Value
$1,120,000.00
Owned After
121,503
SEC Form 4
Chief Technology & Quality Ofc
Avg Cost/Share
$26.00
Shares
40,000
Total Value
$1,040,000.00
Owned After
121,503
SEC Form 4
President, Orexin Program
Avg Cost/Share
$25.00
Shares
8,000
Total Value
$200,000.00
Owned After
181,369
SEC Form 4
General Counsel
Avg Cost/Share
$22.41
Shares
6,000
Total Value
$134,439.00
Owned After
105,386
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Accardi Mario Alberto | CNTA | President, Orexin Program | Dec 9, 2025 | Sell | $28.95 | 10,000 | $288,288.91 | 181,369 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Nov 17, 2025 | Sell | $27.64 | 6,000 | $165,835.20 | 105,386 | |
| Bush Tia L | CNTA | Chief Technology & Quality Ofc | Nov 17, 2025 | Sell | $28.00 | 40,000 | $1,120,000.00 | 121,503 | |
| Bush Tia L | CNTA | Chief Technology & Quality Ofc | Nov 12, 2025 | Sell | $26.00 | 40,000 | $1,040,000.00 | 121,503 | |
| Accardi Mario Alberto | CNTA | President, Orexin Program | Oct 27, 2025 | Sell | $25.00 | 8,000 | $200,000.00 | 181,369 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Oct 15, 2025 | Sell | $22.41 | 6,000 | $134,439.00 | 105,386 |
Compare CNTA vs Leading Stocks
See how CNTA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.